Insurance Coverage of Dermabrasion and Chemical Peel Procedures: A Critical Analysis of 58 American Insurance Companies.

acne treatment chemical peel dermabrasion insurance coverage skin cancers

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Dec 2022
Historique:
accepted: 31 12 2022
entrez: 2 2 2023
pubmed: 3 2 2023
medline: 3 2 2023
Statut: epublish

Résumé

Introduction Dermabrasion and chemical peels are infrequently utilized methods of treatment for medical-grade conditions despite demonstrations of favorable outcomes. Insurance coverage status has previously been shown to impact availability and accessibility to specific treatments. The purpose of this study is to evaluate the rate of insurance coverage provided for dermabrasion and chemical peel procedures in the treatment of acne, acne scarring, and non-melanoma skin cancers (NMSC). Methods A cross-sectional analysis of 58 insurance companies by web-based search or phone interview determined the number of insurers with a publicly available policy on dermabrasion or chemical peels. Coverage status and any corresponding criteria were extracted from existing company policies. Results Thirteen (22%) and 22 (38%) policies discussed dermabrasion in the treatment of basal cell carcinoma and actinic keratosis, with 62% and 73% of these policies providing coverage. Acne scarring was discussed in significantly more dermabrasion policies than basal cell carcinoma (45% vs 22%; p=0.018). However, significantly more insurers denied coverage of dermabrasion for active acne and acne scarring when compared to dermabrasion to treat basal cell carcinoma or actinic keratosis (p<0.001). Eighty-seven percent of companies (n=20) with a chemical peel policy for premalignant lesions would provide coverage, with required criteria present in 95% (n=19) of the policies that would cover chemical peels for actinic keratosis specifically. Of the 25 companies (43%) that discussed the treatment of acne with chemical peel procedures, 14 (56%) provided coverage, and 11 (44%) denied coverage. Coverage was denied by significantly less insurers for the treatment of active acne with chemical peel procedures compared to treatment with dermabrasion (44% vs 83%; p<0.006). Conclusion Significant discrepancies were noted in both the presence of a public policy and the coverage status of dermabrasion or chemical peel procedures among the United States health insurance companies. These inconsistencies, along with multiple criteria required for coverage, may create an artificial barrier to receiving care for specific medical-grade conditions.

Identifiants

pubmed: 36726896
doi: 10.7759/cureus.33184
pmc: PMC9886408
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e33184

Informations de copyright

Copyright © 2022, Ha et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Am Acad Dermatol. 2008 Oct;59(4):659-76
pubmed: 18662839
Arch Dermatol. 2006 Aug;142(8):976-82
pubmed: 16924046
Dermatol Surg. 1996 Jan;22(1):17-21
pubmed: 8556252
Clin Interv Aging. 2013;8:29-35
pubmed: 23345970
J Cosmet Dermatol. 2011 Sep;10(3):202-9
pubmed: 21896132
J Am Acad Dermatol. 2018 Mar;78(3):540-559
pubmed: 29331385
J Dtsch Dermatol Ges. 2006 Dec;4(12):1027-36
pubmed: 17176410
J Vasc Surg Venous Lymphat Disord. 2022 Nov;10(6):1367-1375
pubmed: 35963504
JAMA Dermatol. 2018 Apr 1;154(4):456-459
pubmed: 29490358
J Clin Aesthet Dermatol. 2015 May;8(5):33-40
pubmed: 26029333
J Am Acad Dermatol. 1986 Apr;14(4):661-8
pubmed: 3958276
Lasers Med Sci. 2022 Mar;37(2):1255-1263
pubmed: 34365550
JAMA Dermatol. 2015 Jun;151(6):623-6
pubmed: 25793290
J Cosmet Dermatol. 2018 Oct;17(5):802-810
pubmed: 30203434
Clin Dermatol. 2008 Mar-Apr;26(2):200-8
pubmed: 18472061
J Investig Dermatol Symp Proc. 2004 Mar;9(2):111-9
pubmed: 15083776
Indian J Dermatol Venereol Leprol. 2008 Jan;74 Suppl:S28-36
pubmed: 18688101
Dermatol Surg. 2006 Aug;32(8):1045-9
pubmed: 16918567
Br J Dermatol. 2007 Feb;156(2):222-30
pubmed: 17223860
Arch Dermatol. 1995 Feb;131(2):176-81
pubmed: 7857114
J Vasc Surg Venous Lymphat Disord. 2022 Jul;10(4):929-936
pubmed: 35364303
Nature. 2021 Oct;598(7880):235-236
pubmed: 34621038
J Clin Aesthet Dermatol. 2015 Jan;8(1):50-8
pubmed: 25610524

Auteurs

Michael Ha (M)

Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Maryland School of Medicine, Baltimore, USA.

Emily R Finkelstein (ER)

Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Miami Miller School of Medicine, Miami, USA.

Mark Wieland (M)

Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Maryland School of Medicine, Baltimore, USA.

Aasheen Qadri (A)

Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Maryland School of Medicine, Baltimore, USA.

Madeline Brown (M)

Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Maryland School of Medicine, Baltimore, USA.

Jason Ejimogu (J)

Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Maryland School of Medicine, Baltimore, USA.

Yvonne M Rasko (YM)

Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Maryland School of Medicine, Baltimore, USA.

Classifications MeSH